Equivalence of freeze-dried and liquid-frozen formulations of MVA-BN as smallpox and mpox vaccine
Modified Vaccinia Ankara Bavarian Nordic (MVA-BN) as a smallpox and mpox vaccine has been approved in its liquid-frozen (LF) formulation in the US, Canada, and EU. A freeze-dried (FD) formulation may offer additional benefits, such as a longer shelf life and reduced dependence on cold chain storage...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2384189 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850185277139582976 |
|---|---|
| author | Richard N. Greenberg Darja Schmidt Daniela Reichhardt Siegfried Roesch Sanja Vidojkovic Jane Maclennan Liddy M. Chen Robert Gruenert Christian Kreusel Heinz Weidenthaler Thomas P.H. Meyer Paul John Chaplin |
| author_facet | Richard N. Greenberg Darja Schmidt Daniela Reichhardt Siegfried Roesch Sanja Vidojkovic Jane Maclennan Liddy M. Chen Robert Gruenert Christian Kreusel Heinz Weidenthaler Thomas P.H. Meyer Paul John Chaplin |
| author_sort | Richard N. Greenberg |
| collection | DOAJ |
| description | Modified Vaccinia Ankara Bavarian Nordic (MVA-BN) as a smallpox and mpox vaccine has been approved in its liquid-frozen (LF) formulation in the US, Canada, and EU. A freeze-dried (FD) formulation may offer additional benefits, such as a longer shelf life and reduced dependence on cold chain storage and transport. In a phase 2 clinical trial, 651 vaccinia-naïve participants were vaccinated with two doses of MVA-BN LF or FD, 4 weeks apart. The objectives were to compare MVA-BN FD with LF in terms of vaccine-induced immune responses, safety, and reactogenicity. Non-inferiority of the immune response was assessed by the 95% CI of the geometric mean ratios. Both formulations induced robust vaccinia-specific humoral and cellular immune responses. At peak humoral responses (Week 6), geometric means of total antibody titers were 1096 (95% CI 1013, 1186) from the FD group and 877 (95% CI 804, 956) from the LF group, achieving the primary endpoint of non-inferiority of MVA-BN FD compared to MVA-BN LF. At peak cellular responses (Week 2), geometric means of T cell spot forming units were 449 (95% CI 341, 590) from the FD group and 316 (95% CI 234, 427) from the LF group. Both formulations of MVA-BN were well tolerated, with similar unsolicited AEs and solicited systemic reactions in both groups but slightly more local reactions in the FD group. No vaccine-related serious adverse events (SAEs) or vaccine-related AE of special interest were reported. The FD formulation of MVA-BN was shown to be equivalent to MVA-BN LF. |
| format | Article |
| id | doaj-art-9dfbc757892c4d0a9cd1e16270fc036e |
| institution | OA Journals |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-9dfbc757892c4d0a9cd1e16270fc036e2025-08-20T02:16:46ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2384189Equivalence of freeze-dried and liquid-frozen formulations of MVA-BN as smallpox and mpox vaccineRichard N. Greenberg0Darja Schmidt1Daniela Reichhardt2Siegfried Roesch3Sanja Vidojkovic4Jane Maclennan5Liddy M. Chen6Robert Gruenert7Christian Kreusel8Heinz Weidenthaler9Thomas P.H. Meyer10Paul John Chaplin11Division of Infectious Diseases, University of Kentucky School of Medicine, Lexington, KY, USAClinical Testing, Quality Control Munich, Bavarian Nordic GmbH, Martinsried, GermanyClinical Operations, CatalYm GmbH, Martinsried, GermanyClinical Operations, Topas Therapeutics GmbH, Hamburg, GermanyClinical Testing, Quality Control Munich, Bavarian Nordic GmbH, Martinsried, GermanyClinical Testing, Quality Control Munich, Bavarian Nordic GmbH, Martinsried, GermanyClinical Biometrics, Bavarian Nordic Inc, Durham, NC, USAClinical Testing, Quality Control Munich, Bavarian Nordic GmbH, Martinsried, GermanyClinical Testing, Quality Control Munich, Bavarian Nordic GmbH, Martinsried, GermanyClinical Testing, Quality Control Munich, Bavarian Nordic GmbH, Martinsried, GermanyInstitute of Infectious Diseases and Tropical Medicine, LMU University Hospital, Munich, GermanyExecutive Management, Bavarian Nordic A/S, Hellerup, DenmarkModified Vaccinia Ankara Bavarian Nordic (MVA-BN) as a smallpox and mpox vaccine has been approved in its liquid-frozen (LF) formulation in the US, Canada, and EU. A freeze-dried (FD) formulation may offer additional benefits, such as a longer shelf life and reduced dependence on cold chain storage and transport. In a phase 2 clinical trial, 651 vaccinia-naïve participants were vaccinated with two doses of MVA-BN LF or FD, 4 weeks apart. The objectives were to compare MVA-BN FD with LF in terms of vaccine-induced immune responses, safety, and reactogenicity. Non-inferiority of the immune response was assessed by the 95% CI of the geometric mean ratios. Both formulations induced robust vaccinia-specific humoral and cellular immune responses. At peak humoral responses (Week 6), geometric means of total antibody titers were 1096 (95% CI 1013, 1186) from the FD group and 877 (95% CI 804, 956) from the LF group, achieving the primary endpoint of non-inferiority of MVA-BN FD compared to MVA-BN LF. At peak cellular responses (Week 2), geometric means of T cell spot forming units were 449 (95% CI 341, 590) from the FD group and 316 (95% CI 234, 427) from the LF group. Both formulations of MVA-BN were well tolerated, with similar unsolicited AEs and solicited systemic reactions in both groups but slightly more local reactions in the FD group. No vaccine-related serious adverse events (SAEs) or vaccine-related AE of special interest were reported. The FD formulation of MVA-BN was shown to be equivalent to MVA-BN LF.https://www.tandfonline.com/doi/10.1080/21645515.2024.2384189Modified vaccinia Ankarasmallpoxmonkeypoxmpoxvaccinefreeze-dried |
| spellingShingle | Richard N. Greenberg Darja Schmidt Daniela Reichhardt Siegfried Roesch Sanja Vidojkovic Jane Maclennan Liddy M. Chen Robert Gruenert Christian Kreusel Heinz Weidenthaler Thomas P.H. Meyer Paul John Chaplin Equivalence of freeze-dried and liquid-frozen formulations of MVA-BN as smallpox and mpox vaccine Human Vaccines & Immunotherapeutics Modified vaccinia Ankara smallpox monkeypox mpox vaccine freeze-dried |
| title | Equivalence of freeze-dried and liquid-frozen formulations of MVA-BN as smallpox and mpox vaccine |
| title_full | Equivalence of freeze-dried and liquid-frozen formulations of MVA-BN as smallpox and mpox vaccine |
| title_fullStr | Equivalence of freeze-dried and liquid-frozen formulations of MVA-BN as smallpox and mpox vaccine |
| title_full_unstemmed | Equivalence of freeze-dried and liquid-frozen formulations of MVA-BN as smallpox and mpox vaccine |
| title_short | Equivalence of freeze-dried and liquid-frozen formulations of MVA-BN as smallpox and mpox vaccine |
| title_sort | equivalence of freeze dried and liquid frozen formulations of mva bn as smallpox and mpox vaccine |
| topic | Modified vaccinia Ankara smallpox monkeypox mpox vaccine freeze-dried |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2384189 |
| work_keys_str_mv | AT richardngreenberg equivalenceoffreezedriedandliquidfrozenformulationsofmvabnassmallpoxandmpoxvaccine AT darjaschmidt equivalenceoffreezedriedandliquidfrozenformulationsofmvabnassmallpoxandmpoxvaccine AT danielareichhardt equivalenceoffreezedriedandliquidfrozenformulationsofmvabnassmallpoxandmpoxvaccine AT siegfriedroesch equivalenceoffreezedriedandliquidfrozenformulationsofmvabnassmallpoxandmpoxvaccine AT sanjavidojkovic equivalenceoffreezedriedandliquidfrozenformulationsofmvabnassmallpoxandmpoxvaccine AT janemaclennan equivalenceoffreezedriedandliquidfrozenformulationsofmvabnassmallpoxandmpoxvaccine AT liddymchen equivalenceoffreezedriedandliquidfrozenformulationsofmvabnassmallpoxandmpoxvaccine AT robertgruenert equivalenceoffreezedriedandliquidfrozenformulationsofmvabnassmallpoxandmpoxvaccine AT christiankreusel equivalenceoffreezedriedandliquidfrozenformulationsofmvabnassmallpoxandmpoxvaccine AT heinzweidenthaler equivalenceoffreezedriedandliquidfrozenformulationsofmvabnassmallpoxandmpoxvaccine AT thomasphmeyer equivalenceoffreezedriedandliquidfrozenformulationsofmvabnassmallpoxandmpoxvaccine AT pauljohnchaplin equivalenceoffreezedriedandliquidfrozenformulationsofmvabnassmallpoxandmpoxvaccine |